Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
12.96
+0.15 (1.13%)
Nov 5, 2024, 3:49 PM EST - Market open

Immunome Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Revenue
10.7814.02----
Upgrade
Cost of Revenue
57.7522.9323.11---
Upgrade
Gross Profit
-46.96-8.91-23.11---
Upgrade
Selling, General & Admin
25.5619.8213.7911.094.781.53
Upgrade
Research & Development
---14.117.498.82
Upgrade
Operating Expenses
25.5619.8213.7925.212.2610.35
Upgrade
Operating Income
-72.53-28.73-36.9-25.2-12.26-10.35
Upgrade
Interest Expense
----0.01-0.04-0.11
Upgrade
Interest & Investment Income
92.720.01--0.01
Upgrade
Other Non Operating Income (Expenses)
-----5.54-
Upgrade
EBT Excluding Unusual Items
-63.53-26-36.9-25.21-17.84-10.44
Upgrade
Other Unusual Items
---0.5--
Upgrade
Pretax Income
-262.59-106.81-36.9-24.71-17.84-10.44
Upgrade
Net Income
-262.59-106.81-36.9-24.71-17.84-10.44
Upgrade
Preferred Dividends & Other Adjustments
--0.62---
Upgrade
Net Income to Common
-262.59-106.81-37.52-24.71-17.84-10.44
Upgrade
Shares Outstanding (Basic)
4220121231
Upgrade
Shares Outstanding (Diluted)
4220121231
Upgrade
Shares Change (YoY)
242.29%63.64%5.10%240.41%209.85%0.66%
Upgrade
EPS (Basic)
-6.31-5.38-3.09-2.14-5.26-9.55
Upgrade
EPS (Diluted)
-6.31-5.38-3.09-2.14-5.26-9.55
Upgrade
Free Cash Flow
-65.53-8.4-28.94-18.31-12.72-9.83
Upgrade
Free Cash Flow Per Share
-1.57-0.42-2.39-1.59-3.75-8.99
Upgrade
Gross Margin
--63.54%----
Upgrade
Operating Margin
-672.53%-204.94%----
Upgrade
Profit Margin
-2435.02%-761.92%----
Upgrade
Free Cash Flow Margin
-607.69%-59.92%----
Upgrade
EBITDA
-71.56-28.27-36.48-24.45-11.51-9.73
Upgrade
EBITDA Margin
--201.68%----
Upgrade
D&A For EBITDA
0.970.460.420.760.760.62
Upgrade
EBIT
-72.53-28.73-36.9-25.2-12.26-10.35
Upgrade
EBIT Margin
--204.94%----
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.